Terns Pharma Presents Updated And Expanded Data From Ongoing CARDINAL Trial Of TERN-701 In Patients With Previously Treated CML At ASH Annual Meeting And Exposition

64% MMR achievement by 24 weeks across all efficacy evaluable patients 

75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD

Encouraging safety/tolerability profile maintained with longer duration of treatment

Company to host investor update call today at 4:30pm ET

FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025 in Orlando, FL. The company will host a conference call and webcast for investors at 4:30pm ET today following the ASH presentation.